Phenyl salicylate

Therapeutic Area: Musculo-skeletal system • EU DMF available • US DMF no. 11405 available • Japanese DMF available • CEP available

Indication: Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) used for the management of mild to moderate pain, fever, and inflammation.

Therapeutic Area: Musculo-skeletal system • EU DMF available • US DMF no. 25638 available • Chinese DMF - under registration

Indication: Ibradronic Sodium is a potent bisphosphonate drug used in the prevention and treatment of osteoporosis

Therapeutic Area: Nervous System • EU DMF available • US DMF no. 20548 available • Chinese DMF - under registration • Japanese DMF • CEP available

Indication: Lamotrigine is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder.

Mechanism of action: Effects in the brain and spinal cord to relieve pain via rather unique mechanisms. Firstly it increases the activity of serotonin, norepinephrine and dopamine, neurotransmitters involved in, among other things, pain signalling. Secondly it modulates sodium and calcium channel...

Therapeutic Area: Nervous System • EU DMF available

Indication: Atypical tricyclic antidepressant and anxiolytic agent. It exhibits no reuptake inhibiting properties, but rather acts as an antagonist at D2, 5-HT2 and H1 receptors and binds with high affinity to sigma1 and sigma2 receptors (Ki val...

Therapeutic Area: Cardiovascular system • EU DMF available • US DMF no. 20976 available • Chinese DMF under registration • CEP available
Indication: Pentoxifylline improves blood flow through peripheral blood vessels and therefore helps with blood circulation in the arms and legs (e.g. intermi...

Therapeutic Area: Nervous SystemEU DMF available

Indication:  Antimyoclonic agent.  It is indicated for the treatment of corticol myoclonus, psycho-organic syndrome, vertigo and associated disorders of balance and dyslexia in children.

Therapeutic Area: Antipyretic, analgesic and anti-inflammatory • EU DMF available
Indication: Salicylamide is a non-prescription drug with analgesic and antipyretic properties.

Therapeutic area: Genito-urinary system & sex hormones  • EU DMF available • US DMF no. 23930 available • Japanese DMF available • Chinese DMF available • CEP available
Indication: Sildenafil Citrate is an anti hypertensive, anti erectile dysfunction agent.  It is used for ...

Therapeutic Area: Antipyretic, analgesic and anti-inflammatory • EU DMF available • US DMF no. 26873 available
Indication: Sodium salicylate also acts as non-steroidal anti-inflammatory drug (NSAID)

Therapeutic Area: Genito-urinary system & sex hormones  • EU DMF available  • US DMF no. 24345 available  • CEP - available in December 2016
Indication: used to treat overactive bladder (frequency and urgency). It controls bladder incontinence by controlling contractions.
...

Therapeutic Area: Nervous System • EU DMF available • US DMF no. 20581 available
Indication: anti-epileptic or anti-seizure drug. It is indicated for treatment of partial onset seizures or primary generalized tonic-clonic seizures and adjunctive therapy in patients 6 years of age and o...

Recent investments in Polpharma API’ capabilities will support a strategic move into complex API development and manufacturing for CDMO partners and generics companies worldwide, empowering the global supply chain. Learn how Polpharma API enters into a strategic transformation process that aims to invest in new capabilities and technologies like high containment or cryogenic to be fully implemented by 2026. However, our production capacity will increase significantly already from mid-2023! 

Polpharma API is a Poland-based CDMO and manufacturer of active pharmaceutical ingredients (APIs), that is proceeding with a $45-million manufacturing expansion of its main API plant in Starogard Gdanski to include HPAPI and cryogenic technologies and investments in a pilot plant and R&D capabilities.

We are a Poland-based CDMO and manufacturer of active pharmaceutical ingredients (APIs), that is proceeding with a $45-million manufacturing expansion of its main API plant in Starogard Gdanski to include HPAPI and cryogenic technologies and investments in a pilot plant and R&D capabilities. We expect to extend our operations starting from mid-2023 with full completion scheduled for Q1 2024.

We offer an attractive portfolio of FDF focused on the newest and most prescribed therapies, having a customer centric approach through a multidisciplinary support team: Sales, Marketing, R&D, RA, QA&QC, IP, etc. Due to combined efforts of Polpharma and its strategic partner Farmaprojects we guarantee supply continuity in EU and non-EU territories.

In July 2018, the pharmaceutical industry was shaken when nitrosamine impurities were detected in human medicines, leading to recalls of several batches of high blood pressure and heart failure med valsartan. Investigations by health authorities and drug companies revealed that nitrosamines are generated during the synthesis of active pharmaceutical ingredients (APIs). Read our safe approach in delivering nitrosamine-free at Polpharma API products.

Karina Boszko, head of API Regulatory Affairs and Customer Technical Support Department, explains how we at Polpharma undertake this challenge.


The full article available: https://www.api.polpharma.com/news/safe-approach-in-delivering-nitrosamine-free-api-products/

In the pharmaceutical industry, particle size has become one of the key aspects inthe development of the active pharmaceutical ingredients (APIs) and qualitycontrol of solid oral dosage forms. The physicochemical and biopharmaceutical properties of biologically active substance can be highlyaffected by crystal size and its distribution (CSD), also called as particle size distribution (PSD). According to thelatest scientific reports, it is estimated that almost 80% of new promising molecules having biological activity are rejected during the research and development process due to the low water solubility what is strongly related tothe bioavailability and release of the drug. Polpharma API has many years of experience in delivering APIs with the right particles size distribution through crystallization, milling/micronization, vibration sieving or other technologies. Learn more from our experts!

Recent investments in Polpharma API’ capabilities will support a strategic move into complex API development and manufacturing for CDMO partners and generics companies worldwide, empowering the global supply chain.Visit us and learn how Polpharma API enters into a strategic transformation process that aims to invest in new capabilities and technologies like high containment or cryogenic to be fully implemented by 2026. However, our production capacity will increase significantly already from mid-2023!

Would like to meet our representatives and learn more, please contact us today: [email protected]; [email protected]

Check out how we can create business value together in the whole pharmaceutical value chain, including API, B2B, commercial partnerships and other forms of collaboration. In the video: Markus Sieger, CEO of Polpharma Group, David Gonzalez, Commercial Director of API Business Unit, Mieczyslaw Starkowicz, Head of B2B Venture and Simon Clark, Commercial Director for Polpharma Group and strategic partners.

In 2022, we are opening a new chapter in the history of Polpharma in the field of ​​active substances. With the strategic investment in a HPAPI facility, Polpharma and Poland are becoming a strong pillar of the European pharmaceutical industry in the coming decades.

You can read a full article: https://www.api.polpharma.com/news/polpharmas-strategic-investment-in-hpapi-facility-the-first-of-this-kind-in-poland/